Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal

Fineline Cube Jan 8, 2026
Company Deals

ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M

Fineline Cube Jan 8, 2026
Company Deals

Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront

Fineline Cube Jan 8, 2026
Company Deals

Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy

Fineline Cube Jan 8, 2026
Company Deals

Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance

Fineline Cube Jan 8, 2026
Policy / Regulatory

NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs

Fineline Cube Jan 6, 2026
Company Drug

Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer

Fineline Cube Jan 8, 2026
Company Deals Drug

Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal

Fineline Cube Jan 8, 2026
Company Drug

Antengene ATG-022 CLDN18.2 ADC Gets China Nod for Keytruda Combo in Gastric Cancer

Fineline Cube Dec 3, 2025

Antengene Corporation Limited (HKG: 6996) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Drug

MSD MK-2214 Fast Track Alzheimer Data Positive

Fineline Cube Dec 3, 2025

Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) released first‑in‑human data for MK-2214 and MK-1167 in...

Policy / Regulatory

China Drug-Price Registration System Launches with First Batch of 10 Products

Fineline Cube Dec 3, 2025

China’s Drug Price Registration System officially launched today with the first batch of 10 drug...

Company Deals

3SBio HK$3.1B Placement Funds R&D Pipeline for 705, 706, 008

Fineline Cube Dec 3, 2025

3SBio Inc. (HKG: 1530) conditionally agreed to place 105,169,500 shares at HK$29.62 per share, raising...

Company Drug

Generate GB-0895 Asthma Phase III Trials to Enroll 1,600 Patients

Fineline Cube Dec 3, 2025

Generate: Biomedicines today announced plans to initiate two global Phase III clinical trials (SOLAIRIA-1 and...

Company Drug

Henlius HLX14 Denosumab Biosimilar NDA Accepted by China CDE

Fineline Cube Dec 3, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the National Medical Products Administration’s Center for...

Company Deals

New-Radiomedicine Series-D Raises 800M Yuan for Radiopharmaceuticals

Fineline Cube Dec 3, 2025

Chengdu New Radiomedicine Technology Co., Ltd. announced completion of its Series D financing round, raising...

Company Deals Drug

Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment

Fineline Cube Dec 3, 2025

Kura Oncology, Inc. (NASDAQ: KURA) announced completion of the first US commercial sale of KOMZIFTI...

Company Medical Device

Roche cobas-liat Whooping-Cough Test Secures FDA Clearance

Fineline Cube Dec 3, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its cobas liat system-based point‑of‑care test for whooping...

Company Drug

Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors

Fineline Cube Dec 2, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its self-developed investigational new drug, HLX37 (Recombinant...

Company Drug

Leads-Biolabs LBL047 Bispecific Secures China IND Approval for SLE

Fineline Cube Dec 2, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that the National Medical Products Administration (NMPA)...

Company Deals

Shanghai Bao Pharma IPO HKEX Raises HK$1 Billion for Biotech Pipeline

Fineline Cube Dec 2, 2025

Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) successfully listed on the Hong Kong Stock Exchange...

Company Drug

Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval

Fineline Cube Dec 2, 2025

Abbisko Cayman Limited (HKG: 2256) announced that its Investigational New Drug (IND) application for ABSK141,...

Company Drug

AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China

Fineline Cube Dec 2, 2025

AbbVie (NYSE: ABBV) announced that Rinvoq (upadacitinib) has been included in the priority review list...

Company Drug

Lynk Pharma LNK01006 FDA Approval Targets TYK2 for CNS Diseases

Fineline Cube Dec 2, 2025

Lynk Pharmaceuticals Co., Ltd. announced that its self‑developed TYK2 allosteric inhibitor LNK01006 has received FDA...

Others

FDA Prasad Outlines New Vaccine Approval Process After Covid-19 Safety Analysis

Fineline Cube Dec 2, 2025

Dr. Vinay Prasad, FDA’s chief medical and scientific officer, announced plans to overhaul the vaccine...

Hospital Policy / Regulatory

China Health: Life Expectancy Hits 79 Years as Hospitals Expand and Expenditure Controlled

Fineline Cube Dec 2, 2025

The National Health Commission released the Statistical Bulletin on China’s Health Undertakings 2024, showing China’s...

Company Drug

CANbridge’s maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus

Fineline Cube Dec 2, 2025

CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that maralixibat has been approved by the Department of...

Company Deals

WuXi Biologics CRDMO Qatar MOU Establishes First Middle East Center

Fineline Cube Dec 2, 2025

WuXi Biologics (HKG: 2269) announced it has signed a strategic Memorandum of Understanding (MOU) with...

Company Drug

Johnson & Johnson’s Nipocalimab Secures EU Approval for Myasthenia Gravis

Fineline Cube Dec 2, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission has granted Marketing Authorisation...

Posts pagination

1 … 12 13 14 … 605

Recent updates

  • Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer
  • Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal
  • Sanofi’s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia
  • Bayer’s Cevatertinib Wins Breakthrough Therapy Designation for HER2‑Mutant NSCLC
  • ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer

Company Deals Drug

Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal

Company Drug

Sanofi’s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia

Company Drug

Bayer’s Cevatertinib Wins Breakthrough Therapy Designation for HER2‑Mutant NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.